Last reviewed · How we verify
NCT05203484: EMPIRE-VT
Effect of Multielectrode Versus Point-by-Point Mapping on Recurrence of Ventricular Tachycardia in Ischemic Heart Disease
NA trial testing Multielecotrde Mapping in Ventricular Tachycardia in 180 participants. Suspended.
30 July 2023
Quick facts
| Lead sponsor | Helios Health Institute GmbH |
|---|---|
| Phase | NA |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 180 |
| Start date | 1 October 2022 |
| Primary completion | 30 July 2023 |
| Estimated completion | 30 July 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Multielecotrde Mapping
- Point-by-point mapping
Conditions studied
- Ventricular Tachycardia — all drugs for Ventricular Tachycardia →
Sponsor
Helios Health Institute GmbH
Who can join
Adults 18 to 80, any sex, with Ventricular Tachycardia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
VT ablation is a frequently performed intervention in patients with symptomatic ventricular tachycardia, electrical storm due to monomorphic VT and appropriate ICD shocks, primarily aiming at reducing the burden of complaints, and ICD shocks. The recommendations for its use were described in the ESC guideline for ventricular arrhythmias and the prevention of sudden cardiac death. To visualize the arrhythmogenic substrate leading to ventricular tachycardia complex mapping techniques are currently used in clinical routine, including conventional Point-by-Point mapping or Multielectrode Mapping. The latter is associated with shorter Mapping and overall procedure times, while maintaining the same primary endpoint of the procedure itself. The aim of this trial is to validate, whether the reduction of mapping and procedure time is associated with a comparable long-term outcome compared with conventional Point-by-Point mapping.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05203484
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ventricular Tachycardia
Currently open trials in the same condition.
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
- NCT06360939 — Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease · NA · recruiting
- NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
- NCT06891456 — Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia · NA · recruiting
- NCT06592001 — Assessment of a Chronically Implanted Parasternally Delivered EV-ICD Lead (ASCEND EV) Study · NA · active not recruiting
Other Helios Health Institute GmbH trials
Trials by the same sponsor.
- NCT05389631 — Trifecta and Epic ViV Detailed Insights Into Management Strategies and Outcomes · completed
- NCT05133843 — Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Impl · NA · recruiting
- NCT04844931 — Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction · NA · active not recruiting
- NCT04844944 — The Helios Heart Registry: A Standardized Registry for Patients With Specific Cardiac Diseases · recruiting
- NCT05709756 — Prevalence and Predictors of Esophageal Thermal Lesions in High-power-Short-duration Ablation of Atrial Fibrillation · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05203484 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helios Health Institute GmbH
- Last refreshed: 19 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203484.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing